These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32087611)

  • 1. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.
    Wang Y; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Br J Pharmacol; 2020 Jul; 177(13):3060-3074. PubMed ID: 32087611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.
    Wang Y; Sparidans RW; Wang J; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2022 Jan; 170():197-207. PubMed ID: 34952136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
    Wang Y; Sparidans RW; Potters S; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2021 Oct; 172():105850. PubMed ID: 34450308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib.
    Li W; Sparidans RW; Martins MLF; El-Lari M; Lebre MC; van Tellingen O; Beijnen JH; Schinkel AH
    Mol Cancer Ther; 2021 Jun; 20(6):1173-1182. PubMed ID: 33785654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
    Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.
    Li W; Lehutová D; Sparidans RW; Heydari P; Wang J; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2022 Aug; 177():135-146. PubMed ID: 35772614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 limits brain exposure of the KRAS
    Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.
    Martínez-Chávez A; Broeders J; Lebre MC; Tibben MT; Rosing H; Beijnen JH; Schinkel AH
    Eur J Pharm Sci; 2021 Apr; 159():105740. PubMed ID: 33524505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
    Martínez-Chávez A; Loos NHC; Lebre MC; Tibben MM; Rosing H; Beijnen JH; Schinkel AH
    Pharmacol Res; 2022 Apr; 178():105954. PubMed ID: 34700018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
    Wang J; Bruin MAC; Gan C; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Pharm; 2020 May; 581():119277. PubMed ID: 32234426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
    Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.
    F Martins ML; Loos NHC; Mucuk S; de Jong D; Lebre MC; Rosing H; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2021 Dec; 18(12):4371-4384. PubMed ID: 34730366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
    van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
    Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).
    Wang Y; Sparidans RW; Potters S; Şentürk R; Lebre MC; Beijnen JH; Schinkel AH
    Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.